Table 1. Characteristics of included studies.
| Study | Study Design | Study Population (age distribution) | Study Location | Sample type | Commercial name of Ag-RDT used | Clinical presentation at the time of testing | Sample size (Male/Female) |
|---|---|---|---|---|---|---|---|
| Diao, 2021 [18] | Prospective study | Adults (16–75 years) | China | NPS | Not available | Symptomatic | 251 (122/129) |
| Agrawal, 2021 [19] | Prospective study | Adults and Children (2–85 years) | India | NS | Standard Q COVID-19 Ag test (SD Biosensor) | Symptomatic and Asymptomatic | 467 (239/228) |
| Kim, 2021 [20] | Prospective & retrospective study | Not Specified | India | NPS | GenbodyCOVID-19 Ag test COVAG025 | Symptomatic and Asymptomatic | 200 (not specified) |
| Nalumansi,2020 [16] | Prospective cross-sectional study | Adults (31–39 years) | Uganda | NS | Standard Q COVID-19 Ag test (SD Biosensor) | Symptomatic and Asymptomatic | 262 (234/28) |
| Boum, 2021 [21] | Prospective study | Adults (at least 21 years) | Cameroon | NPS | SD Biosensor test | Symptomatic and Asymptomatic | 1090(not specified) |
| Pena-Rodriguez, 2021 [15] | Prospective cross-sectional study | Not Specified, Mean age: 36.6±13.16 | Mexico | NPS/OPS | Standard Q COVID-19 Ag test (SD Biosensor) | Symptomatic and Asymptomatic | 369 (154/215) |
| Gupta, 2021 [22] | Prospective cross-sectional study | Adults (>18 years) | India | NPS | Standard Q COVID-19 Ag test (SD Biosensor) | Symptomatic and Asymptomatic | 330 (231/99) |
| Chaimayo, 2020 [23] | Prospective study | Adults (21–72 years) | Thailand | NPS and TS, ETA, Sp. | Standard Q COVID-19 Ag test (SD Biosensor) | Symptomatic and Asymptomatic | 454(not specified) |
| Shrestha, 2020 [17] | Prospective observational study | Adults and Children (13–72 years) | Nepal | NPS | RapiGEN—BIOCREDIT COVID-19 Ag | Asymptomatic | 113 (24/89) |
| Ristic, 2021 [24] | Prospective study | Adults and Children (14–91 years) | Serbia | NPS | Standard Q COVID-19 Ag test (SD Biosensor) | Symptomatic | 120 (63/57) |
| Thakur, 2021 [25] | Prospective cross- sectional study | Adults (18–89 years) | India | NPS and OPS | PathoCatch/ACCUCARE | Asymptomatic | 677 (372/305) |
| Kanaujia, 2021 [26] | Prospective cross-sectional study | Adults and Children (13–90 years) | India | NPS | Coris bioconcept COVID-19 ag respi-strip test | Symptomatic and Asymptomatic | 484 (261/223) |
NPS = Nasopharyngeal Swab, NS = Nasal Swab, OPS = Oropharyngeal Swab, TS = Throat Swab, ETA = Endotracheal Aspirate, Sp. = Sputum.